



---

# DEVONIAN

---

DEVONIAN HEALTH GROUP INC.

**PRESS RELEASE**

*For immediate release*

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

## **Devonian Announces Issuance of One New Key Patent and the Granting of a Trademark.**

QUEBEC, June 21, 2017 – Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) a clinical stage botanical pharmaceutical corporation, announces today that the U.S. Patent and Trademark Office has recently issued Patent #9,555,068, entitled "Oral compositions and route of administration for the delivery of a thylakoid extract". The patent covers the oral delivery of thylakoid extract for treating or preventing a disease or disorder involving the formation of reactive oxygen species and inflammation in individuals. The patent also covers the use of thylakoids as a food or a food supplement, as a pellet, as encapsulated granules or powder.

"We are very excited to have received additional patent protection covering oral delivery of thylakoids. The new patent covers several delivery formulations of thylakoids, the active ingredient of our lead product Thykamine™," said Dr Andre P. Boulet, President & CEO of Devonian"

The Corporation also announces that the U.S. Patent and Trademark Office has recently granted a trademark for R-Spinasome®, the active ingredient of its Purgenesis™ derma-cosmetic products.

"The granting of a trademark to R-Spinasome®, the active ingredient of our Purgenesis™ anti-aging treatment (patent-pending), has a significant impact within our Intellectual Property (IP) strategy. Our IP strategy includes patents and trademarks as a pair in order to provide higher economic value to our shareholders. We apply this strategy to our pharmaceutical and derma-cosmeceutical programs. " adds Dr. Boulet.

### **About Thykamine™**

Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform is a highly innovative product to be used in the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, skin aging, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory



properties of Thykamine™ have been demonstrated by an impressive number of *in vitro* and *in vivo* studies as well as in a Phase 2a clinical study in patients with mild-to-moderate distal ulcerative colitis. Thykamine™ is currently under development for ulcerative colitis and atopic dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia.

### **About PurGenesis™ anti-aging treatment**

PurGenesis™ anti-aging treatment has three components: a day cream, a night cream and an eye cream. These creams contain R-Spinasome® complex, an active structure of pigments, proteins and lipids extracted from organic baby spinach. The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides R-Spinasome® complex with unprecedented, long-lasting anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to evaluate the performance of PurGenesis™ Anti-aging product line compared with two other leading prestige brands over a 28 day period of use. The results indicate that PurGenesis™ anti-aging line is significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration effects. PurGenesis™ anti-aging treatment is patent-pending worldwide with the exception of Japan where a patent was issued (#JP 5952261).

### **About Devonian**

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX). The "Thykamine™" is the first product issued from this platform. The potent anti-inflammatory and anti-oxidative activities of "Thykamine™" have been demonstrated in several pre-clinical experiments as well as in a Phase 2a "proof of concept" clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase 2 clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.



## **Forward Looking Statements**

This press release contains forward-looking statements about Devonian's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian's prospectus dated April 21<sup>st</sup>, 2017 under the heading "Risk Factors" related to Devonian's business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact: Dr. André P. Boulet, PhD  
President and Chief Executive Officer  
Devonian Health Group Inc.  
Telephone: (514) 248-7509  
e-mail: [apboulet@groupe-devonian.com](mailto:apboulet@groupe-devonian.com)